Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
about
Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult miceChemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative StressEvaluation and management of patients with heart disease and cancer: cardio-oncologySerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsNoninvasive imaging of cardiovascular injury related to the treatment of cancerRapid Extracorporeal Membrane Oxygenation Overcomes Fulminant Myocarditis Induced by 5‑Fluorouracil.Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in miceModulation of vincristine and doxorubicin binding and release from silk filmsCancer drug related cardiotoxicity during breast cancer treatment.Noninvasive diagnosis of chemotherapy related cardiotoxicityCardio-oncology: a new medical issue.Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.Iron in chronic brain disorders: imaging and neurotherapeutic implications.Acute coronary syndrome induced by oral capecitabine.Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat modelIschemic Heart Disease: Special Considerations in Cardio-Oncology.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionCardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsCharacterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.BCNU-induced gR2 defect mediates S-glutathionylation of Complex I and respiratory uncoupling in myocardium.Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeCardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor StudyReview of cardiotoxicity in pediatric cancer patients: during and after therapy.Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction.Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome.Proanthocyanidins produce significant attenuation of doxorubicin-induced mutagenicity via suppression of oxidative stress.Cardiotoxic effects of anthracycline-taxane combinations.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivorsSerial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohortA comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.
P2860
Q24632487-C97634C0-E5B5-44EE-8BF1-03BCC3900C8AQ26780547-8C600F09-4A5D-42F8-9188-1D608F263A7CQ26998273-0A3EAABE-353B-404C-84E1-94B65EBB74FEQ27007849-1652C0B6-380E-4891-962C-F7673B30CE4FQ27024715-7F321108-950A-4C84-AD9F-FAD8769B3458Q27348720-4781618B-CAB3-4F45-8255-B2957EE0E6B2Q28360954-8D9CD288-382F-4D9C-BB73-B8E8A479655DQ28829218-3CA4FB0D-F22C-4B32-A36C-3753519C20FCQ30251498-427E7358-7438-4452-93B2-3566F28A593BQ30461444-4D449C3F-9CA5-4E8C-ABCE-23330129DD1AQ30471284-533FCE2B-1633-4EAD-A956-277721576F88Q30540353-780CCDCB-12E5-4212-832E-856B9FDB4CD5Q31117154-E5D2891A-0CA8-4D21-AE64-6BF4BC534309Q33235644-F1D820C4-3B17-41C2-BDDF-3904D40145FCQ33404672-B9C440E0-D0D9-4172-8700-BD18EFAC08DAQ33441165-FC9DA3E9-DC06-4194-8AE7-EBECDAE2B334Q33574045-B4984D12-A78C-46D0-8C38-7EE5D5DC9301Q33619867-5D58E1E8-2E54-48F3-A3DC-D15D7D6F88F2Q33645678-F04DE6FD-99C8-451E-8D1E-6D861CFD88A7Q33671207-F536DF17-6FA5-449A-AE8B-8AA44915BBE0Q33692818-631BD537-FD08-44E1-9155-49F5C1C643ACQ33710233-77002565-3932-40D9-B9A1-20AD363CF0C9Q33899881-5E96E973-2BA5-48B1-B927-69A07CC4BCC3Q34257903-9C8970C0-3CD3-4323-A327-625960B517CAQ34333236-C986E4A5-7607-47AE-866B-451E21450697Q34394131-9117C201-B1F6-45F1-A176-531A935145E9Q34627978-5B85F81F-405D-44E3-AAA7-7564EBFAE7B7Q34659375-123B2147-E12D-47BA-93E6-304CEC4FB935Q34835391-B563B597-6FE3-4286-A91D-6C4BCEAE9515Q35008126-D140293B-E87D-4DDA-ABED-5F830966685AQ35082301-B6973AA7-A670-4C05-B188-5E072D667E02Q35124414-FE258037-1130-40B0-B2B0-53A46F059923Q35157976-6A95F2D6-7E84-4058-90CC-12C2F6D5FF48Q35194442-EADC1AAC-98DF-4028-9248-21D07ADFECEBQ35490056-7E757993-4327-4C23-8C88-913D73C35196Q35557142-A3ADEF8F-28CE-465B-9953-53031CE922A3Q35623306-CA7FF9C6-3CA8-4B8E-A239-7317771FEA8CQ35699184-71519DD0-9DD7-4285-923F-4FB0EF07CAF8Q35753383-F55C6E76-7862-41A9-8D06-7C9986CCE9D1Q35909105-993014ED-BB98-4BF5-AA3F-C2B5CBC782A4
P2860
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@ast
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@en
type
label
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@ast
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@en
prefLabel
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@ast
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@en
P1433
P1476
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
@en
P2093
P304
P356
10.2165/00002018-200022040-00002
P577
2000-04-01T00:00:00Z
P6179
1038629765